Online inquiry

IVTScrip™ mRNA-Anti-CD274, BCD-135(Cap 1, 5-Methyl-CTP, 120 nt-poly(A))   (CAT#: GTTS-WQ3920MR)

This product GTTS-WQ3920MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & 5-Methyl-CTP. It ecodes the monoclonal antibody that targets CD274 gene. The antibody can be applied in Solid tumors research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP
5' Cap Cap 1
Species Homo sapiens
RefSeq NM_001267706.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 29126
UniProt ID Q9NZQ7
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CD274, BCD-135(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) (GTTS-WQ3920MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ14636MR IVTScrip™ mRNA-Anti-DLL3, SC0001-SCX(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA SC0001-SCX
GTTS-WQ15495MR IVTScrip™ mRNA-Anti-FCGRT, UCB-7665(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA UCB-7665
GTTS-WQ5868MR IVTScrip™ mRNA-Anti-IFNAR1&IFNAR2, CIFN(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA CIFN
GTTS-WQ15937MR IVTScrip™ mRNA-Anti-Felcat NGF, ZTS-00084768(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA ZTS-00084768
GTTS-WQ12335MR IVTScrip™ mRNA-Anti-TIGIT, MTIG-7192-A(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA MTIG-7192-A
GTTS-WQ11266MR IVTScrip™ mRNA-Anti-CD274, MEDI4736(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA MEDI4736
GTTS-WQ10524MR IVTScrip™ mRNA-Anti-PCSK9, LY-3015014(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA LY-3015014
GTTS-WQ2125MR IVTScrip™ mRNA-Anti-CGRP, ALD-403(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA ALD-403
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW